Inhibitory Effects On Retinal Neovascularization by Ranibizumab and sTie2-Fc in An Oxygen-Induced Retinopathy Mouse Model

References

• Stone J, Chan-Ling T, Pe'er j, Itin A, Gnessin H, keshet E. Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 1996 Feb;37(2):290–9
   Google Scholar
• Nguyen QD, Tatlipinar S, Shah SM, Haller JA, Quinlan E, Sung J, Zimmer-Galler I, Do DV, Campochiaro PA. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol. 2006 Dec;142(6):961–9. doi:10.1016/j.ajo.2006.06.068.
   Google Scholar
• Miller JW, Le Couter J, Strauss EC, Ferrara N. Vascular endothelial growth factor a in intraocular vascular disease. Ophthalmology. 2013 Jan;120(1):106–14. doi:10.1016/j.ophtha.2012.07.038
   Google Scholar
• Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, Gibson A, Sy J, Rundle AC, Hopkins JJ et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012 Apr;119(4):789–801. doi:10.1016/j.ophtha.2011.12.039.
   PubMed Web of Science ®Google Scholar
• Vander JF, McNamara JA, Tasman W, Brown GC Revised indications for early treatment of retinopathy of prematurity. Arch Ophthalmol. 2005 Mar;123(3):406–07. discussion 9-10. doi:10.1001/archopht.123.3.406-b.
   PubMedGoogle Scholar
• Quinn GE, Darlow BA Concerns for development after bevacizumab treatment of ROP. Pediatrics. 2016 Apr;137(4). doi:10.1542/peds.2016-0057.
   Web of Science ®Google Scholar
• Wu WC, Lien R, Liao PJ, Wang NK, Chen YP, Chao AN, Chen KJ, Chen TL, Hwang YS, Lai CC. Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity. JAMA Ophthalmol. 2015 Apr;133(4):391–97. doi:10.1001/jamaophthalmol.2014.5373.
   PubMed Web of Science ®Google Scholar
• Sato T, Wada K, Arahori H, Kuno N, Imoto K, Iwahashi-Shima C, Kusaka S. Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol. 2012 Feb;153(2):327–33 e1. doi:10.1016/j.ajo.2011.07.005.
   PubMed Web of Science ®Google Scholar
• Avery RL. Bevacizumab (Avastin) for retinopathy of prematurity: wrong dose, wrong drug, or both? J AAPOS. 2012 Feb;16(1):2–4. doi:10.1016/j.jaapos.2011.11.002.
   PubMed Web of Science ®Google Scholar
• Is KA. Avastin the right choice of treatment for retinopathy of prematurity? Acta Paediatr. 2012 Aug;101(8):796–98. doi:10.1111/j.1651-2227.2012.02757.x.
   PubMed Web of Science ®Google Scholar
• Morin J, Luu TM, Superstein R, Ospina LH, Lefebvre F, Simard MN, Shah V, Shah PS, Kelly EN Neurodevelopmental Outcomes Following Bevacizumab Injections for Retinopathy of Prematurity. Pediatrics. 2016 Apr;137(4). doi:10.1542/peds.2015-3218.
   PubMed Web of Science ®Google Scholar
• Kook D, Wolf A, Kreutzer T, Neubauer A, Strauss R, Ulbig M, Kampik A, Haritoglou C. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema. Retina. 2008 Oct;28(8):1053–60. doi:10.1097/IAE.0b013e318176de48.
   PubMed Web of Science ®Google Scholar
• Nuti E, Traversi C, Marigliani D, Balestrazzi A, Alegente M, Martone G, Malandrini A, Romeo N, Mazzotta C, Tosi GM. Treatment of macular edema because of occlusive vasculitis with bevacizumab (avastin): efficacy of three consecutive monthly injections. Retina. 2011 Oct;31(9):1863–70. doi:10.1097/IAE.0b013e318219de8b.
   PubMed Web of Science ®Google Scholar
• Wong RK, Hubschman S, Tsui I. Reactivation of retinopathy of prematurity after ranibizumab treatment. Retina. 2015 Apr;35(4):675–80. doi:10.1097/iae.0000000000000578.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Shah SM, Khwaja AA, Channa R, Hatef E, Do DV, Boyer D, Heier JS, Abraham P, Thach AB et al. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology. 2010 Nov;117(11):2146–51. doi:10.1016/j.ophtha.2010.08.016.
   PubMed Web of Science ®Google Scholar
• Rodrigues EB, Farah ME, Maia M, Penha FM, Regatieri C, Gb M, Pinheiro MM, Zanetti CR. Therapeutic monoclonal antibodies in ophthalmology. Prog Retin Eye Res. 2009 Mar;28(2):117–44. doi:10.1016/j.preteyeres.2008.11.005.
   PubMed Web of Science ®Google Scholar
• Saint-Geniez M, Maharaj AS, Walshe TE, Tucker BA, Sekiyama E, Kurihara T, Darland DC, Young MJ, D’Amore PA. Endogenous VEGF is required for visual function: evidence for a survival role on muller cells and photoreceptors. PLoS One. 2008;3(11):e3554. doi:10.1371/journal.pone.0003554.
   PubMed Web of Science ®Google Scholar
• Wu WC, Kuo HK, Yeh PT, Yang CM, Lai CC, Chen SN. An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in taiwan. Am J Ophthalmol. 2013 Jan;155(1):150–8 e1. doi:10.1016/j.ajo.2012.06.010.
   PubMed Web of Science ®Google Scholar
• Augustin HG, Koh GY, Thurston G, Alitalo K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol. 2009 Mar;10(3):165–77. doi:10.1038/nrm2639.
   PubMed Web of Science ®Google Scholar
• Hackett SF, Ozaki H, Strauss RW, Wahlin K, Suri C, Maisonpierre P, Yancopoulos G, Campochiaro PA. Angiopoietin 2 expression in the retina: upregulation during physiologic and pathologic neovascularization. J Cell Physiol. 2000 Sep;184(3):275–84. doi:10.1002/1097-4652(200009)184:3<275::aid-jcp1>3.0.co;2-7.
   PubMed Web of Science ®Google Scholar
• Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997 Jul 04;277(5322):55–60. doi:10.1126/science.277.5322.55.
   PubMed Web of Science ®Google Scholar
• Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, Yancopoulos GD. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell. 1996 Dec 27;87(7):1171–80. doi:10.1016/S0092-8674(00)81813-9.
   PubMed Web of Science ®Google Scholar
• Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Ryan TE, Bruno J, Radziejewski C, Maisonpierre PC et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell. 1996 Dec 27;87(7):1161–69. doi:10.1016/S0092-8674(00)81812-7.
   PubMed Web of Science ®Google Scholar
• Oh N, Kim K, Kim SJ, Park I, Lee JE, Seo YS, An HJ, Kim HM, Koh GY. A designed angiopoietin-1 variant, dimeric CMP-Ang1 activates Tie2 and stimulates angiogenesis and vascular stabilization in N-glycan dependent manner. Sci Rep. 2015 Oct;19(5):15291. doi:10.1038/srep15291.
   Google Scholar
• Thurston G, Suri C, Smith K, McClain J, Sato TN, Yancopoulos GD, McDonald DM. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science. 1999 Dec 24;286(5449):2511–14. doi:10.1126/science.286.5449.2511.
   PubMed Web of Science ®Google Scholar
• Shen J, Frye M, Lee BL, Reinardy JL, McClung JM, Ding K, Kojima M, Xia H, Seidel C, Lima E Silva R et al. Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature. J Clin Invest. 2014 Oct;124(10):4564–76. doi:10.1172/jci74527.
   PubMed Web of Science ®Google Scholar
• Smith LE, Wesolowski E, McLellan A, Kostyk SK, D’Amato R, Sullivan R, D’Amore PA. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994 Jan;35(1):101–11.
   PubMed Web of Science ®Google Scholar
• Connor KM, Krah NM, Dennison RJ, Aderman CM, Chen J, Guerin KI, Sapieha P, Stahl A, Willett KL, Smith LE. Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis. Nat Protoc. 2009;4(11):1565–73. doi:10.1038/nprot.2009.187.
   PubMed Web of Science ®Google Scholar
• Hartnett ME. Pathophysiology and mechanisms of severe retinopathy of prematurity. Ophthalmology. 2015 Jan;122(1):200–10. doi:10.1016/j.ophtha.2014.07.050.
   PubMed Web of Science ®Google Scholar
• Lepore D, Quinn GE, Molle F, Baldascino A, Orazi L, Sammartino M, Purcaro V, Giannantonio C, Papacci P, Romagnoli C. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. Ophthalmology. 2014 Nov;121(11):2212–19. doi:10.1016/j.ophtha.2014.05.015.
   PubMed Web of Science ®Google Scholar
• Yi Z, Su Y, Zhou Y, Zheng H, Ye M, Xu Y, Chen C. Effects of intravitreal ranibizumab in the treatment of retinopathy of prematurity in Chinese infants. Curr Eye Res. 2016 Aug;41(8):1092–97. doi:10.3109/02713683.2015.1084643.
   PubMed Web of Science ®Google Scholar
• Hangai M, Moon YS, Kitaya N, Chan CK, Wu DY, Peters KG, Ryan SJ, Hinton DR. Systemically expressed soluble Tie2 inhibits intraocular neovascularization. Hum Gene Ther. 2001 Jul 01;12(10):1311–21. doi:10.1089/104303401750270968.
   PubMed Web of Science ®Google Scholar
• Singh N, Macnamara E, Rashid S, Ambati J, Kontos CD, Higgins E, Ambati BK. Systemic soluble Tie2 expression inhibits and regresses corneal neovascularization. Biochem Biophys Res Commun. 2005 Jun 24;332(1):194–99. doi:10.1016/j.bbrc.2005.04.108.
   PubMed Web of Science ®Google Scholar
• Oliner JD, Bready J, Nguyen L, Estrada J, Hurh E, Ma H, Pretorius J, Fanslow W, Nork TM, Leedle RA et al. AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, inhibits angiogenesis in models of ocular neovascular diseases. Invest Ophthalmol Vis Sci. 2012 Apr 24;53(4):2170–80. doi:10.1167/iovs.11-7381.
   PubMed Web of Science ®Google Scholar
• Oshima Y, Deering T, Oshima S, Nambu H, Reddy PS, Kaleko M, Connelly S, Hackett SF, Campochiaro PA. Angiopoietin-2 enhances retinal vessel sensitivity to vascular endothelial growth factor. J Cell Physiol. 2004 Jun;199(3):412–17. doi:10.1002/jcp.10442.
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Khanani A, Singer M, Patel S, Boyer D, Dugel P, Kherani S, Withers B, Gambino L, Peters K et al. Enhanced benefit in diabetic macular edema from AKB-9778 Tie2 activation combined with vascular endothelial growth factor suppression. Ophthalmology. 2016 Aug;123(8):1722–30. doi:10.1016/j.ophtha.2016.04.025.
   PubMed Web of Science ®Google Scholar
• Nakao S, Arima M, Ishikawa K, Kohno R, Kawahara S, Miyazaki M, Yoshida S, Enaida H, Hafezi-Moghadam A, Kono T et al. Intravitreal anti-VEGF therapy blocks inflammatory cell infiltration and re-entry into the circulation in retinal angiogenesis. Invest Ophthalmol Vis Sci. 2012 Jun 28;53(7):4323–28. doi:10.1167/iovs.11-9119.
   PubMed Web of Science ®Google Scholar
• Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011 Feb 17;364(7):603–15. doi:10.1056/NEJMoa1007374.
   PubMed Web of Science ®Google Scholar
• Zhao R, Qian L, Jiang L. miRNA-dependent cross-talk between VEGF and Ang-2 in hypoxia-induced microvascular dysfunction. Biochem Biophys Res Commun. 2014 Sep 26;452(3):428–35. doi:10.1016/j.bbrc.2014.08.096.
   PubMed Web of Science ®Google Scholar
• Huang H, Shen J, Vinores SA. Blockade of VEGFR1 and 2 suppresses pathological angiogenesis and vascular leakage in the eye. PLoS One. 2011;6(6):e21411. doi:10.1371/journal.pone.0021411.
   PubMed Web of Science ®Google Scholar